Diabetes & EndocrinologyimmunotherapyLong-Term Safety
Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
By MedXY|Jun 19, 2026
Extended follow-up of participants from 14 randomized trials found no excess self-reported serious adverse outcomes after type 1 diabetes immunotherapy, supporting continued long-term surveillance.